ATRC
What one share of AtriCure holds
Surgical and Medical Instruments and Apparatus
We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic.
AtriCure’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $11.74 |
|---|---|
| Profit | $0.22 |
| Capex (buildings and equipment) | $0.24 |
| Free cash flow | $1.09 |
| Cash and investments | $3.30 |
| Debt | $1.33 |
| Book value | $10.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $3.74 | −$1.13 | $0.09 | −$0.06 | — | $1.17 |
| 2010 | $3.91 | −$0.25 | $0.12 | −$0.12 | — | $1.07 |
| 2011 | $4.11 | −$0.35 | $0.10 | −$0.22 | — | $0.95 |
| 2012 | $4.34 | −$0.47 | $0.18 | −$0.30 | — | $0.74 |
| 2013 | $4.01 | −$0.56 | $0.14 | −$0.40 | — | $3.12 |
| 2014 | $4.07 | −$0.61 | $0.21 | −$1.03 | — | $4.81 |
| 2015 | $4.62 | −$0.97 | $0.48 | −$0.76 | — | $5.78 |
| 2016 | $4.91 | −$1.05 | $0.24 | −$0.72 | — | $5.05 |
| 2017 | $5.39 | −$0.83 | $0.20 | −$0.47 | — | $4.66 |
| 2018 | $5.92 | −$0.62 | $0.18 | −$0.30 | — | $6.46 |
| 2019 | $6.14 | −$0.94 | $0.32 | −$0.74 | — | $6.24 |
| 2020 | $4.90 | −$1.14 | $0.12 | −$0.60 | — | $9.09 |
| 2021 | $5.96 | $1.09 | $0.21 | −$0.51 | — | $10.51 |
| 2022 | $7.22 | −$1.02 | $0.37 | −$0.85 | — | $9.81 |
| 2023 | $8.62 | −$0.66 | $0.26 | −$0.16 | — | $9.81 |
| 2024 | $9.91 | −$0.95 | $0.24 | $0.02 | — | $9.43 |
| 2025 | $11.19 | −$0.24 | $0.19 | $1.01 | — | $9.88 |